Results 181 to 190 of about 38,667 (276)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV. [PDF]

PLoS One, 2022
Morsica G, Galli L, Messina E, Castagna A, Bagaglio S, Salpietro S, Liviana DT, Uberti-Foppa C, Hasson H.   +8 more
europepmc   +1 more source

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

SIV monoclonal antibody administration spanning treatment interruption in macaques delays viral rebound and selects escape variants. [PDF]

Proc Natl Acad Sci U S A
King HAD, Brammer D, Lewitus E, Fennessey CM, Manalang KM, Shrader HR, Andrew S, Kuri P, Lind M, Pham P, Sanders-Buell E, Bai H, Mason R, Song K, McCarthy E, Helmold Hait S, Todd JP, Pegu A, Foulds KE, Lifson JD, Keele BF, Rolland M, Roederer M, Bolton DL.   +23 more
europepmc   +1 more source

Unified model of short- and long-term HIV viral rebound for clinical trial planning. [PDF]

J R Soc Interface, 2021
Conway JM, Meily P, Li JZ, Perelson AS.
europepmc   +1 more source

HIV rebound is predominantly fueled by viral expansions from diverse reservoirs

, 2019
info:eu-repo/semantics ...
De Scheerder, Marie-Angélique, Vrancken, Bram, Dellicour, Simon, Schlub, Timothy, Lee, Eunok, Shao, Wei, Rutsaert, Sofie, Verhofstede, Chris, Kerre, Tessa, Malfait, Thomas L A, Hemelsoet, Dimitri, Coppens, Marc, Dhondt, Annemieke, De Looze, Danny, Vermassen, Frank, Lemey, Philippe, Palmer, Sarah, Vandekerckhove, Linos   +17 more
openaire   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

Clinical Pharmacology &Therapeutics, EarlyView.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

Longitudinal assessments of viral rebound among people with HIV in South Carolina: a population-based cohort study. [PDF]

AIDS Care
Xiao J, Yang X, Ma Y, Olatosi B, Weissman S, Li X, Zhang J.   +6 more
europepmc   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Contribution of intact viral genomes persisting in blood and tissues during ART to plasma viral rebound in SHIV-infected rhesus macaques. [PDF]

iScience
Trifone C, Richard C, Pagliuzza A, Dufour C, Lemieux A, Clark NM, Janaka SK, Fennessey CM, Keele BF, Fromentin R, Estes JD, Kaufmann DE, Finzi A, Evans DT, Chomont N.   +14 more
europepmc   +1 more source

Early Initiation of Antiretroviral Therapy Following In Utero HIV Infection Is Associated With Low Viral Reservoirs but Other Factors Determine Viral Rebound. [PDF]

J Infect Dis, 2021
Millar JR, Bengu N, Vieira VA, Adland E, Roider J, Muenchhoff M, Fillis R, Sprenger K, Ntlantsana V, Fatti I, Archary M, Groll A, Ismail N, García-Guerrero MC, Matthews PC, Ndung'u T, Puertas MC, Martinez-Picado J, Goulder P.   +18 more
europepmc   +1 more source